Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19957822 | 0.81 | ESR1 (0.33) | CCNT1CDK9ESR1MAP3K12HRH3 | |
| SCHEMBL15830325 | 0.81 | CCNT1 (0.49) | CCNT1CDK9MAP3K12HRH3 | |
| SCHEMBL17303780 | 0.81 | CCNT1 (0.40) | CCNT1CDK9MAP3K12 | |
| SCHEMBL19957555 | 0.77 | CCNT1 (0.33) | CCNT1CDK9ESR1MAP3K12HRH3 | |
| SCHEMBL17300768 | 0.77 | CCNT1 (0.38) | CCNT1CDK9MAP3K12 | |
| SCHEMBL17383741 | 0.77 | ESR1 (0.31) | CCNT1CDK9ESR1HRH3 | |
| SCHEMBL15834078 | 0.77 | RXRA (0.32) | CCNT1CDK9ESR1HRH3 | |
| SCHEMBL15834104 | 0.77 | PRMT5 (0.37) | ESR1 | |
| SCHEMBL20252401 | 0.75 | CCNT1 (0.36) | CCNT1CDK9MAP3K12 | |
| SCHEMBL15834093 | 0.74 | CCNT1 (0.46) | CCNT1CDK9HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | CCNT1 2718/4885CDK9 398/4885ESR1 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.